Tilray Brands (NASDAQ:TLRY) Trading Up 6.7% on Analyst Upgrade

Tilray Brands, Inc. (NASDAQ:TLRY)’s stock price shot up 6.7% during mid-day trading on Thursday after Roth Mkm upgraded the stock from a neutral rating to a buy rating. Roth Mkm now has a $10.00 price target on the stock. Tilray Brands traded as high as $6.66 and last traded at $6.55. 5,508,183 shares were traded during mid-day trading, an increase of 49% from the average session volume of 3,697,357 shares. The stock had previously closed at $6.14.

Several other research analysts also recently commented on TLRY. Zacks Research upgraded Tilray Brands from a “strong sell” rating to a “hold” rating in a research note on Wednesday, February 11th. Canaccord Genuity Group assumed coverage on Tilray Brands in a report on Tuesday, January 27th. They set a “hold” rating for the company. Wall Street Zen raised shares of Tilray Brands from a “sell” rating to a “hold” rating in a research report on Saturday, March 21st. TD Cowen decreased their price objective on shares of Tilray Brands from $10.00 to $7.00 and set a “buy” rating on the stock in a report on Monday. Finally, ATB Cormark Capital Markets raised shares of Tilray Brands from a “strong sell” rating to a “hold” rating in a research report on Wednesday, December 10th. Three equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Tilray Brands has a consensus rating of “Hold” and an average target price of $11.20.

More Tilray Brands News

Here are the key news stories impacting Tilray Brands this week:

• Positive Sentiment: Roth upgraded Tilray to Buy after Q3 results, citing the company’s improving outlook and execution—this upgrade helped lift sentiment. Tilray rebounds as Roth Capital upgrades to Buy after Q3 results
• Positive Sentiment: Jefferies reiterated a Buy and kept a high $24 price target, highlighting strong cannabis sales and increased visibility into medium‑term results—this signals confidence from a major broker. Tilray Brands’ strong cannabis sales and upbeat outlook keeps Jefferies analysts bullish
• Positive Sentiment: Tilray reported record Q3 revenue (~$207M), 11% organic growth, gross profit expansion (~$55M) and a 73% jump in international cannabis revenue—management reaffirmed FY26 guidance, which supports the constructive narrative. Tilray Brands Delivers Record Q3 Fiscal 2026 Results
• Positive Sentiment: Sector tailwind: the FDA signaled it won’t enforce some CBD rules, which lifted cannabis/CBD names broadly and supports Tilray’s consumer-facing opportunity. Why Tilray and Other Cannabis Stocks Just Had Their Best Week of 2026
• Neutral Sentiment: Zacks and other analysts describe Q3 as mixed—revenue and narrowing losses are positives, but beverage weakness and margin pressure temper the bullish case. Should Tilray Brands Be in Your Portfolio Post Q3 Earnings?
• Neutral Sentiment: Analysis pieces note improving fundamentals but flag negative cash flow and execution/M&A risk—supportive for medium-term upside but caution on near-term volatility. Tilray Brands Is Looking Better
• Negative Sentiment: Tilray missed EPS expectations (loss of $0.24 vs. est. -$0.14), and investors have been wary of margin compression and beverage-segment softness—these factors triggered earlier intraday selling. Earnings and conference call details
• Negative Sentiment: Some analysts trimmed targets/ratings after the print: ATB Cormark cut its target to $9.00 (sector perform) and TD Cowen lowered expectations—mixed analyst action adds selling pressure at current levels. Analyst rating changes TD Cowen lowers expectations

Institutional Trading of Tilray Brands

Several hedge funds have recently added to or reduced their stakes in TLRY. Hilton Head Capital Partners LLC bought a new stake in Tilray Brands in the 4th quarter valued at $38,000. Schonfeld Strategic Advisors LLC grew its holdings in Tilray Brands by 4.5% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 144,358 shares of the company’s stock valued at $1,304,000 after buying an additional 6,182 shares in the last quarter. IFP Advisors Inc increased its position in Tilray Brands by 14.3% during the 4th quarter. IFP Advisors Inc now owns 60,318 shares of the company’s stock worth $545,000 after buying an additional 7,541 shares during the period. Integrated Wealth Concepts LLC lifted its holdings in shares of Tilray Brands by 33.8% during the third quarter. Integrated Wealth Concepts LLC now owns 36,977 shares of the company’s stock worth $64,000 after buying an additional 9,341 shares in the last quarter. Finally, CreativeOne Wealth LLC lifted its holdings in shares of Tilray Brands by 12.2% during the third quarter. CreativeOne Wealth LLC now owns 87,134 shares of the company’s stock worth $151,000 after buying an additional 9,452 shares in the last quarter. 9.35% of the stock is owned by institutional investors and hedge funds.

Tilray Brands Stock Performance

The stock’s 50-day moving average price is $7.32 and its 200-day moving average price is $10.23. The company has a market cap of $763.14 million, a P/E ratio of -0.48 and a beta of 2.00. The company has a debt-to-equity ratio of 0.19, a current ratio of 2.81 and a quick ratio of 1.72.

Tilray Brands (NASDAQ:TLRY) last released its quarterly earnings results on Wednesday, April 1st. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.10). Tilray Brands had a negative return on equity of 3.31% and a negative net margin of 156.51%.The business had revenue of $206.73 million for the quarter, compared to the consensus estimate of $201.35 million. During the same period in the prior year, the business posted ($0.87) earnings per share. Equities analysts anticipate that Tilray Brands, Inc. will post -0.2 EPS for the current year.

Tilray Brands Company Profile

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.